Cytokinetics (NASDAQ:CYTK – Get Free Report) and Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Cytokinetics and Inhibrx Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cytokinetics | 1 | 1 | 19 | 0 | 2.86 |
| Inhibrx Biosciences | 1 | 2 | 2 | 1 | 2.50 |
Cytokinetics presently has a consensus target price of $105.44, indicating a potential upside of 69.17%. Inhibrx Biosciences has a consensus target price of $197.50, indicating a potential upside of 103.40%. Given Inhibrx Biosciences’ higher probable upside, analysts plainly believe Inhibrx Biosciences is more favorable than Cytokinetics.
Institutional and Insider Ownership
82.5% of Inhibrx Biosciences shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Cytokinetics and Inhibrx Biosciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cytokinetics | $88.04 million | 88.09 | -$784.96 million | ($7.22) | -8.63 |
| Inhibrx Biosciences | $1.30 million | 1,099.47 | -$140.05 million | ($8.88) | -10.93 |
Inhibrx Biosciences has lower revenue, but higher earnings than Cytokinetics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Cytokinetics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 3.81, indicating that its stock price is 281% more volatile than the S&P 500.
Profitability
This table compares Cytokinetics and Inhibrx Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cytokinetics | -1,321.12% | N/A | -51.01% |
| Inhibrx Biosciences | N/A | -563.90% | -83.48% |
Summary
Inhibrx Biosciences beats Cytokinetics on 8 of the 14 factors compared between the two stocks.
About Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
About Inhibrx Biosciences
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.
